News

Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights

Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues…

1 year ago

Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer

NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing…

1 year ago

Noom Introduces AI-Enabled Products to Enhance On-Demand Health Care and Interactive Coaching

Consumers can now use new AI food logging capabilities and Welli, an AI-powered personal health assistant, to make sustainable habits…

1 year ago

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company…

1 year ago

Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

Additional $6.7M in funding resulting in approximately $67M in gross proceedsNEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc.…

1 year ago

Daré Bioscience Announces Reverse Stock Split

Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) --…

1 year ago

Spectral AI Surpasses 90% of Pediatric Enrollment Target in Burn Centers for Pivotal U.S. Burn Study

DALLAS, June 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence…

1 year ago

TRxADE Health, Inc. Files its Q1 10-Q; Reporting Positive Net Income Due to Asset Sale

TAMPA, FL, June 27, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH Inc. (Nasdaq: MEDS) (the “Company”), announced today that with the…

1 year ago

Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap

MALVERN, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”),…

1 year ago

Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT Trial

Enrollment in SUMMIT Part 2 remains on track for completion in Q2 2025 with top-line results expected by end of…

1 year ago